In the latest session, Caribou Biosciences Inc (NASDAQ: CRBU) closed at $7.34 down -2.13% from its previous closing price of $7.50. In other words, the price has decreased by -$0.16 from its previous closing price. On the day, 1126436 shares were traded.
Ratios:
For a deeper understanding of Caribou Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.27 and its Current Ratio is at 14.27. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
On October 31, 2023, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $13.
On July 11, 2023, Truist started tracking the stock assigning a Buy rating and target price of $23.Truist initiated its Buy rating on July 11, 2023, with a $23 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRBU now has a Market Capitalization of 649.08M and an Enterprise Value of 338.05M. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.75 while its Price-to-Book (P/B) ratio in mrq is 1.63. Its current Enterprise Value per Revenue stands at 9.77 whereas that against EBITDA is -3.19.
Stock Price History:
Over the past 52 weeks, CRBU has reached a high of $8.59, while it has fallen to a 52-week low of $3.44. The 50-Day Moving Average of the stock is 6.25, while the 200-Day Moving Average is calculated to be 5.55.
Shares Statistics:
For the past three months, CRBU has traded an average of 1.57M shares per day and 1.23M over the past ten days. A total of 88.43M shares are outstanding, with a floating share count of 77.73M. Insiders hold about 12.10% of the company’s shares, while institutions hold 79.63% stake in the company. Shares short for CRBU as of Feb 15, 2024 were 9.69M with a Short Ratio of 6.18, compared to 9.86M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.96% and a Short% of Float of 11.50%.
Earnings Estimates
There are 7 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.37 for the current quarter, with a high estimate of -$0.21 and a low estimate of -$0.44, while EPS last year was -$0.44. The consensus estimate for the next quarter is -$0.41, with high estimates of -$0.34 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.17 and -$1.46 for the fiscal current year, implying an average EPS of -$1.37. EPS for the following year is -$1.74, with 8 analysts recommending between -$1.6 and -$1.87.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $4.61M this quarter.It ranges from a high estimate of $9.1M to a low estimate of $2M. As of the current estimate, Caribou Biosciences Inc’s year-ago sales were $3.69M, an estimated increase of 24.90% from the year-ago figure.
A total of 8 analysts have provided revenue estimates for CRBU’s current fiscal year. The highest revenue estimate was $40M, while the lowest revenue estimate was $30.92M, resulting in an average revenue estimate of $34.89M. In the same quarter a year ago, actual revenue was $13.85M, up 151.90% from the average estimate.
